JP4109111B2 - 縮合複素環式芳香族グルコキナーゼアクチベーター - Google Patents

縮合複素環式芳香族グルコキナーゼアクチベーター Download PDF

Info

Publication number
JP4109111B2
JP4109111B2 JP2002547912A JP2002547912A JP4109111B2 JP 4109111 B2 JP4109111 B2 JP 4109111B2 JP 2002547912 A JP2002547912 A JP 2002547912A JP 2002547912 A JP2002547912 A JP 2002547912A JP 4109111 B2 JP4109111 B2 JP 4109111B2
Authority
JP
Japan
Prior art keywords
cyclopentyl
phenyl
propionamide
methanesulfonyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002547912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517087A (ja
JP2004517087A5 (US06448399-20020910-C00007.png
Inventor
コーベット，ウェンディ・リー
グリムブシー，ジョセフ・サミュエル
ヘインズ，ナンシー−エレン
ケスター，ロバート・フランシス
マハニー，ペイジ・エリン
サラブ，ラマカンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004517087A publication Critical patent/JP2004517087A/ja
Publication of JP2004517087A5 publication Critical patent/JP2004517087A5/ja
Application granted granted Critical
Publication of JP4109111B2 publication Critical patent/JP4109111B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
JP2002547912A 2000-12-06 2001-11-28 縮合複素環式芳香族グルコキナーゼアクチベーター Expired - Fee Related JP4109111B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25163700P 2000-12-06 2000-12-06
PCT/EP2001/013870 WO2002046173A1 (en) 2000-12-06 2001-11-28 Fused heteroaromatic glucokinase activators

Publications (3)

Publication Number Publication Date
JP2004517087A JP2004517087A (ja) 2004-06-10
JP2004517087A5 JP2004517087A5 (US06448399-20020910-C00007.png) 2005-05-26
JP4109111B2 true JP4109111B2 (ja) 2008-07-02

Family

ID=22952803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002547912A Expired - Fee Related JP4109111B2 (ja) 2000-12-06 2001-11-28 縮合複素環式芳香族グルコキナーゼアクチベーター

Country Status (21)

Country Link
US (3) US6448399B1 (US06448399-20020910-C00007.png)
EP (1) EP1341774B1 (US06448399-20020910-C00007.png)
JP (1) JP4109111B2 (US06448399-20020910-C00007.png)
KR (1) KR100545431B1 (US06448399-20020910-C00007.png)
CN (1) CN1226294C (US06448399-20020910-C00007.png)
AR (1) AR031627A1 (US06448399-20020910-C00007.png)
AT (1) ATE316965T1 (US06448399-20020910-C00007.png)
AU (2) AU2190202A (US06448399-20020910-C00007.png)
BR (1) BR0115999A (US06448399-20020910-C00007.png)
CA (1) CA2429642C (US06448399-20020910-C00007.png)
DE (1) DE60117059T2 (US06448399-20020910-C00007.png)
DK (1) DK1341774T3 (US06448399-20020910-C00007.png)
ES (1) ES2256340T3 (US06448399-20020910-C00007.png)
GT (1) GT200100243A (US06448399-20020910-C00007.png)
MX (1) MXPA03005119A (US06448399-20020910-C00007.png)
PA (1) PA8534301A1 (US06448399-20020910-C00007.png)
PE (1) PE20020753A1 (US06448399-20020910-C00007.png)
PT (1) PT1341774E (US06448399-20020910-C00007.png)
UY (1) UY27055A1 (US06448399-20020910-C00007.png)
WO (1) WO2002046173A1 (US06448399-20020910-C00007.png)
ZA (1) ZA200303748B (US06448399-20020910-C00007.png)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CN1678311A (zh) 2002-06-27 2005-10-05 诺沃挪第克公司 用作治疗剂的芳基羰基衍生物
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
US6775812B2 (en) * 2002-07-17 2004-08-10 Hewlett-Packard Development Company, L.P. Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit
MXPA05003391A (es) 2002-10-03 2005-06-22 Hoffmann La Roche Indol-3-carboxamidas como activadores de glucocinasa.
CN101805358A (zh) 2002-10-03 2010-08-18 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑-2-基)酰胺或磺酰胺
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
MXPA05013733A (es) * 2003-06-20 2006-03-08 Hoffmann La Roche 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
AU2005203930C1 (en) 2004-01-06 2012-02-23 Vtv Therapeutics Llc Heteroaryl-ureas and their use as glucokinase activators
EP1718625A1 (en) * 2004-02-18 2006-11-08 AstraZeneca AB Compounds
ATE426597T1 (de) * 2004-02-18 2009-04-15 Astrazeneca Ab Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
KR100830007B1 (ko) 2004-04-02 2008-05-15 노파르티스 아게 2형 당뇨병 치료에 유용한 글루코키나제 활성화제로서의술폰아미드-티아졸피리딘 유도체
NZ550567A (en) * 2004-04-21 2010-07-30 Prosidion Ltd Tri(cyclo) substituted amide compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
AU2005271016A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
CN101094847B (zh) 2004-11-02 2011-06-15 Msdk.K.公司 芳氧基取代的苯并咪唑衍生物
DE102005012872A1 (de) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2305674A1 (en) * 2005-07-09 2011-04-06 AstraZeneca AB Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
JP5281287B2 (ja) * 2005-07-13 2013-09-04 Ｍｓｄ株式会社 ヘテロ環置換ベンズイミダゾール誘導体
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1931337B1 (en) 2005-09-29 2013-10-23 Sanofi Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
AU2006310474A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AT503354B1 (de) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007143434A2 (en) 2006-05-31 2007-12-13 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
EP2261216A3 (en) 2006-07-24 2011-12-14 F. Hoffmann-La Roche AG Pyrazoles as glucokinase activators
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) * 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
UY30822A1 (es) * 2006-12-21 2008-07-31 Astrazeneca Ab Fnueva forma cristalina de 3-{[5-azetidin-1-ylcabonyl)pyrazin-2-yl]oxy}-5-[1-methylethyloxy]-n-1h-pyrazol-3-ylbenzamida, composiciones conteniéndola, procesos de preparacion y aplicaciones
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
KR20090121376A (ko) 2007-03-07 2009-11-25 교린 세이야꾸 가부시키 가이샤 글루코키나아제 활성화 물질
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
RU2010134411A (ru) 2008-01-18 2012-02-27 Астеллас Фарма Инк. (Jp) Фенилацетамидное производное
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
BRPI0917589A2 (pt) 2008-08-04 2015-11-17 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, método para tratar doenças, processo, combinação farmacêutica, e, reação de metiloxirano-2-carboxilato (ix) com um álcool roh
JP5937353B2 (ja) 2008-08-19 2016-06-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 冷感−メントール受容体拮抗剤
BRPI0918128A2 (pt) 2008-09-11 2015-11-24 Pfizer derivados de heterozril amida e seu uso como ativadores de glicocinase
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
RS52903B (en) 2009-03-11 2014-02-28 Pfizer Inc BENZOFURANIL DERIVATIVES FOR USE AS GLUCOKINASE INHIBITORS
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2828346C (en) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
AU2016262969C1 (en) 2015-05-15 2022-02-24 Aurigene Discovery Technologies Limited Substituted tetrahydroquinolinone compounds as ROR gamma modulators
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840550A (en) * 1971-05-24 1974-10-08 Ciba Geigy Corp Certain 6-isothiocyanobenzothiazoles
JP3884232B2 (ja) * 1999-03-29 2007-02-21 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化物質
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators

Also Published As

Publication number Publication date
MXPA03005119A (es) 2004-10-15
CA2429642C (en) 2007-11-20
CN1476438A (zh) 2004-02-18
BR0115999A (pt) 2003-09-30
EP1341774B1 (en) 2006-02-01
US6545155B2 (en) 2003-04-08
ES2256340T3 (es) 2006-07-16
WO2002046173A1 (en) 2002-06-13
AR031627A1 (es) 2003-09-24
US20020107396A1 (en) 2002-08-08
US20020103241A1 (en) 2002-08-01
US6448399B1 (en) 2002-09-10
CA2429642A1 (en) 2002-06-13
ATE316965T1 (de) 2006-02-15
PA8534301A1 (es) 2002-08-26
AU2002221902B2 (en) 2006-11-23
GT200100243A (es) 2002-06-04
JP2004517087A (ja) 2004-06-10
US20020103199A1 (en) 2002-08-01
PE20020753A1 (es) 2002-08-27
DE60117059D1 (de) 2006-04-13
CN1226294C (zh) 2005-11-09
PT1341774E (pt) 2006-05-31
EP1341774A1 (en) 2003-09-10
ZA200303748B (en) 2004-08-16
AU2190202A (en) 2002-06-18
DE60117059T2 (de) 2006-10-26
DK1341774T3 (da) 2006-06-12
UY27055A1 (es) 2002-07-31
KR100545431B1 (ko) 2006-01-24
US6441184B1 (en) 2002-08-27
KR20030068555A (ko) 2003-08-21

Similar Documents

Publication Publication Date Title
JP4109111B2 (ja) 縮合複素環式芳香族グルコキナーゼアクチベーター
AU2002221902A1 (en) Fused heteroaromatic glucokinase activators
US6433188B1 (en) Fused heteroaromatic glucokinase activators
EP1349856B1 (en) Isoindolin-1-one glucokinase activators
KR100502032B1 (ko) 트랜스 올레핀 글루코키나제 활성화제
EP1311504B1 (en) Tetrazolyl-phenyl acetamide glucokinase activators
JP3839723B2 (ja) 置換フェニルアセトアミドおよびグルコキナーゼ活性化剤としてのその使用
JP3971189B2 (ja) ｐ−アミノ置換フェニルアミドグルコキナーゼ活性化物質
AU2002238415A1 (en) Isoindolin-1-one glucokinase activators
AU2001283998A1 (en) Tetrazolyl-phenyl acetamide glucokinase activators

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070907

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080403

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110411

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120411

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees